HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)

被引：19

作者：

Kikuchi, Kiyoshi ^{[2
]}

Uchikado, Hisaaki ^{[3
]}

Miura, Naoki ^{[6
,7
]}

Morimoto, Yoko ^{[4
]}

Ito, Takashi ^{[1
]}

Tancharoen, Salunya ^{[5
]}

Miyata, Kei ^{[1
]}

Sakamoto, Rokudai ^{[2
]}

Kikuchi, Chiemi ^{[8
]}

Iida, Narumi ^{[9
]}

Shiomi, Naoto ^{[10
]}

Kuramoto, Terukazu ^{[11
]}

Miyagi, Naohisa ^{[2
]}

Kawahara, Ko-Ichi ^{[1
,12
]}

机构：

[1] Kagoshima Univ, Field Cardiovasc & Resp Disorders, Grad Sch Med & Dent Sci, Div Lab & Vasc Med,Dept Adv Therapeut, Kagoshima 8908520, Japan

[2] Yame Publ Gen Hosp, Dept Neurosurg, Yame 8340034, Japan

[3] Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 8300011, Japan

[4] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Restorat Dent & Endodontol, Kagoshima 8908544, Japan

[5] Mahidol Univ, Fac Dent, Dept Pharmacol, Bangkok 10400, Thailand

[6] Kagoshima Univ, Fac Agr, Vet Teaching Hosp, Kagoshima 8900065, Japan

[7] Kagoshima Univ, Fac Agr, Lab Vet Diagnost Imaging, Kagoshima 8900065, Japan

[8] Nishida Koutoku Hosp, Dept Rehabil, Oita 8760047, Japan

[9] Kohjin Co Ltd, Res Lab, Oita 8768580, Japan

[10] Saiseikai Shiga Hosp, Emergency Dept, Shiga 5203046, Japan

[11] Omuta City Gen Hosp, Dept Neurosurg, Fukuoka 8368567, Japan

[12] Osaka Inst Technol, Dept Biomed Engn, Lab Funct Foods, Osaka 5358585, Japan

来源：

EXPERIMENTAL AND THERAPEUTIC MEDICINE | 2011年 / 2卷 / 05期

关键词：

high mobility group box 1; spinal cord injury; transplantation; MOBILITY GROUP BOX-1; OLFACTORY ENSHEATHING CELLS; GLYCATION END-PRODUCTS; PROTEIN; DENDRITIC CELLS; STEM-CELLS; IN-VITRO; RELEASE; ACTIVATION; RECEPTOR;

D O I：

10.3892/etm.2011.310

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

Historically, clinical outcomes following spinal cord injury (SCI) have been dismal. Severe SCI leads to devastating neurological deficits, and there is no treatment available that restores the injury-induced loss of function to a degree that an independent life can be guaranteed. To address all the issues associated with SCI, a multidisciplinary approach is required, as it is unlikely that a single approach, such as surgical intervention, pharmacotherapy or cellular transplantation, will suffice. High mobility group box 1 (HMGB1) is an inflammatory cytokine. Various studies have shown that HMGB I plays a critical role in SCI and that inhibition of HMGB1 release may be a novel therapeutic target for SCI and may support spinal cord repair. In addition, HMGB1 has been associated with graft rejection in the early phase. Therefore, HMGB1 may be a promising therapeutic target for SCI transplant patients. We hypothesize that inhibition of HMGB1 release rescues patients with SCI. Taken together, our findings suggest that anti-HMGB1 monoclonal antibodies or short hairpin RNA-mediated HMGB1 could be administered for spinal cord repair in SCI patients.

引用

页码：767 / 770

页数：4

共 61 条

[1]

HMGB proteins and gene expression [J].